ArticleFrontiers in pharmacology2022
Epigenetic Mechanism of 5-HT/NE/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress Mice.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Pooled it
- Article
- Design, Synthesis, and Biological Evaluation of Novel Morpholine-Coumarin Derivatives for Inflammation-Associated Depression.Biomolecules · 2026Article
- Internet plus-based post-discharge continuity care for mild-to-moderate depression: An exploratory study.World journal of psychiatry · 2026Article
- Transcutaneous auricular vagus nerve stimulation for major depressive disorder: current evidence and future research directions.Frontiers in psychiatry · 2026Review
- The double-edged sword effect of adverse childhood experiences forging adult stress into depression and anxiety.Scientific reports · 2025Article
- Deconvolution-Based Transcriptomic Analysis in the Hippocampus Reveals Cell Type-Specific Risk Genes and Pathways Associated With Depression and Suicide.Biological psychiatry global open science · 2025Article
- Progress in Molecular Mechanisms of Depression Induced by Mother-Infant Separation and Intervention of Traditional Chinese Medicine.Alpha psychiatry · 2025Review
- Exploring the Potential of Coumarin Derivatives on Serotonin Receptors 5-HTInternational journal of molecular sciences · 2025Article
- Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HTJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/HMolecules (Basel, Switzerland) · 2024Article
- Epigenetic Modifications and Neuroplasticity in the Pathogenesis of Depression: A Focus on Early Life Stress.Behavioral sciences (Basel, Switzerland) · 2024Review
- Intertwined associations between oxytocin, immune system and major depressive disorder.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Does urinary metabolite signature act as a biomarker of post-stroke depression?Frontiers in psychiatry · 2022Review
- Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a chronic, remitting and debilitating disease and the etiology of MDD is highly complicated that involves genetic and environmental interactions. Despite many pharmacotherapeutic options, many patients remain poorly treated and the development of effective treatments remains a high priority in the field. LPM570065 is a potent 5-hydroxytryptamine (5-HT), norepinephrine (NE) and dopamine (DA) triple reuptake inhibitor and both preclinical and clinical results demonstrate significant efficacy against MDD. This study extends previous findings to examine the effects and underlying mechanisms of LPM570065 on stress vulnerability using a "two-hit" stress mouse model. The "two-hit" stress model used adult mice that had experienced early life maternal separation (MS) stress for social defeat stress (SDS) and then they were evaluated in three behavioral assays: sucrose preference test, tail suspension test and forced swimming test. For the mechanistic studies, methylation-specific differentially expressed genes in mouse hippocampal tissue and ventral tegmental area (VTA) were analyzed by whole-genome transcriptome analysis along with next-generation bisulfite sequencing analysis, followed by RT-PCR and pyrophosphate sequencing to confirm gene expression and methylation. LPM570065 significantly reversed depressive-like behaviors in the mice in the sucrose preference test, the tail suspension test, and the forced swimming test. Morphologically, LPM570065 increased the density of dendritic spines in hippocampal CA1 neurons. Hypermethylation and downregulation of oxytocin receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.